Back to Newsroom

Debiopharm Group Announces Initiation of a Phase I Study of Debio 1450, an IV/oral Potent Antibiotic Active Against Staphylococcal Infections

Lausanne, Switzerland – June 19, 2014 – Debiopharm Group(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

Click here to read more